Agilent has completed a $21 million strategic investment in Gen9, a Cambridge, Mass based privately-held company that has pioneered the development of scalable technologies for synthesizing genes. The funds will be used to further invest in product development and to expand the commercial infrastructure for Gen9’s synthetic biology business.
Gen9’s portfolio of next-generation gene synthesis technologies form the foundation of the Gen9 BioFab® platform, which has the capacity to synthesize tens of thousands of gene fragments in just a few square feet of laboratory space.
Agilent’s partnership with Gen9 complements the company’s existing investments in synthetic biology, gene synthesis and assembly, including further generations of its oligo synthesis technology. Agilent currently produces the highest-quality long DNA compared to that of any commercially available source.
For more information go to: